What Are Trulicity and Ozempic?
Trulicity (dulaglutide) and Ozempic (semaglutide) are injectable GLP-1 receptor agonists used to manage type 2 diabetes. Both mimic the GLP-1 hormone to boost insulin release, slow digestion, and reduce appetite, lowering blood sugar and supporting weight loss. Trulicity is weekly from Eli Lilly; Ozempic is also weekly from Novo Nordisk.[1][2]
How Do They Perform Head-to-Head?
In trials like SUSTAIN 7, semaglutide (Ozempic) reduced A1C more than dulaglutide (Trulicity): -1.5% to -1.8% vs. -1.4% at 40 weeks, depending on dose. Ozempic also drove greater weight loss (8-10 lbs vs. 6-7 lbs). Both cut cardiovascular risks similarly in heart patients, per REWIND (Trulicity) and SUSTAIN-6 (Ozempic).[3][4]
| Metric | Ozempic (1 mg weekly) | Trulicity (1.5 mg weekly) |
|--------|-----------------------|---------------------------|
| A1C Drop | -1.6% to -1.8% | -1.4% |
| Weight Loss | 8-10 lbs | 6-7 lbs |
| CV Risk Reduction | 26% MACE drop | 12% MACE drop |
Key Differences in Use and Dosing
Ozempic starts at 0.25 mg, ramps to 2 mg max; Trulicity starts at 0.75 mg, max 4.5 mg. Ozempic pens allow finer dose tweaks. Both are once-weekly subcutaneous shots, but Ozempic has off-label weight loss buzz (via Wegovy version), while Trulicity sticks closer to diabetes.[1][2]
Side Effects Patients Report
Both cause nausea, vomiting, diarrhea, and low blood sugar risk—often worse starting out, fading over time. Ozempic edges higher on GI issues in head-to-head data (37% vs. 21% discontinuation for side effects). Rare thyroid tumor warnings apply to both; Ozempic faces more scrutiny for pancreatitis and gastroparesis lawsuits.[3][5]
Cost and Insurance Coverage
Ozempic lists at $936/month, Trulicity at $987—cash prices similar, but coupons drop both under $300 with savings cards. Medicare covers both for diabetes; Ozempic gets edge for obesity if prescribed off-label. Shortages hit Ozempic harder recently.[6]
When Would a Doctor Pick One Over the Other?
Choose Ozempic for max A1C/weight drop or heart benefits; Trulicity if higher doses needed or GI tolerance is priority. No clear winner—depends on response, insurance, and pen preference. Switch if one fails efficacy or tolerability.[4]
Sources:
[1] Trulicity.com
[2] Ozempic.com
[3] NEJM SUSTAIN 7 Trial
[4] REWIND/SUSTAIN-6 CV Data
[5] FDA GLP-1 Warnings
[6] GoodRx Pricing